AC Immune Net Worth

AC Immune Net Worth Breakdown

  ACIU
The net worth of AC Immune is the difference between its total assets and liabilities. AC Immune's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of AC Immune's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. AC Immune's net worth can be used as a measure of its financial health and stability which can help investors to decide if AC Immune is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in AC Immune stock.

AC Immune Net Worth Analysis

AC Immune's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AC Immune's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AC Immune's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AC Immune's net worth analysis. One common approach is to calculate AC Immune's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AC Immune's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AC Immune's net worth. This approach calculates the present value of AC Immune's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AC Immune's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AC Immune's net worth. This involves comparing AC Immune's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AC Immune's net worth relative to its peers.

Enterprise Value

498.09 Million

419391170258128281323498-7%-56%52%-50%118%15%54%100%
To determine if AC Immune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AC Immune's net worth research are outlined below:
AC Immune generated a negative expected return over the last 90 days
The company reported the previous year's revenue of 14.8 M. Net Loss for the year was (54.23 M) with loss before overhead, payroll, taxes, and interest of (20.46 M).
AC Immune currently holds about 154.15 M in cash with (60.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83.
AC Immune has a poor financial position based on the latest SEC disclosures
Roughly 38.0% of the company shares are held by company insiders
Latest headline from news.google.com: AC Immune Leader In Dementia Therapies, A Space Littered With Failures - Seeking Alpha
AC Immune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AC Immune. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AC Immune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
21st of March 2024
Upcoming Quarterly Report
View
26th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know AC Immune's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as AC Immune is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AC Immune backward and forwards among themselves. AC Immune's institutional investor refers to the entity that pools money to purchase AC Immune's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Millennium Management Llc2024-12-31
119 K
Marshall Wace Asset Management Ltd2024-12-31
66.3 K
Geode Capital Management, Llc2024-12-31
64.1 K
Ubs Group Ag2024-12-31
49.7 K
Squarepoint Ops Llc2024-12-31
43.8 K
Two Sigma Investments Llc2024-12-31
40.8 K
Jane Street Group Llc2024-12-31
24.3 K
China Universal Asset Mgmt Co.ltd2024-12-31
21 K
Rpo Llc2024-12-31
18.7 K
Bvf Inc2024-12-31
19.5 M
Blackrock Inc2024-12-31
2.2 M
Note, although AC Immune's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow AC Immune's market capitalization trends

The company currently falls under 'Small-Cap' category with a current market capitalization of 251.32 M.

Market Cap

603.66 Million

Project AC Immune's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.47)(0.45)
Return On Capital Employed(0.29)(0.30)
Return On Assets(0.34)(0.36)
Return On Equity(0.30)(0.32)
The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.
When accessing AC Immune's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AC Immune's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AC Immune's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.

Evaluate AC Immune's management efficiency

AC Immune has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.45 in 2025. Return On Capital Employed is likely to drop to -0.3 in 2025. Total Current Liabilities is likely to drop to about 12.8 M in 2025. Liabilities And Stockholders Equity is likely to drop to about 193.9 M in 2025
Last ReportedProjected for Next Year
Book Value Per Share 1.71  1.70 
Tangible Book Value Per Share 1.17  1.57 
Enterprise Value Over EBITDA(6.24)(6.55)
Price Book Value Ratio 2.55  2.42 
Enterprise Value Multiple(6.24)(6.55)
Price Fair Value 2.55  2.42 
Enterprise Value323.2 M498.1 M
The operational strategies employed by AC Immune management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue
1.7425
Revenue
41 M
Quarterly Revenue Growth
14.8 K
Revenue Per Share
0.425
Return On Equity
(0.31)

AC Immune Corporate Filings

6K
18th of December 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
13A
13th of December 2024
An amended filing to the original Schedule 13G
ViewVerify
26th of July 2024
Other Reports
ViewVerify
AC Immune time-series forecasting models is one of many AC Immune's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AC Immune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

AC Immune Earnings per Share Projection vs Actual

AC Immune Corporate Management

Julian SnowVP DevelopmentProfile
Nuno MDChief OfficerProfile
Christopher RobertsInterim FinProfile
Sonia PoliHead ScienceProfile
Piergiorgio DonatiChief OfficerProfile
Pr MDChief OfficerProfile
Joshua DrummHead RelationsProfile

Already Invested in AC Immune?

The danger of trading AC Immune is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AC Immune is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AC Immune. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AC Immune is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.